Articles
Written for the worker side.
Featured · About Open Label · 2026-07-17
Why Open Label exists
Tech workers have salary sites, anonymous communities, and worker-side trade press. Clinical research has none of the three. That is the whole founding argument.
Read the piece
Careers · 2026-07-23
ACRP or SOCRA: which clinical research certification to actually get
Two credentialing bodies dominate clinical research, and newcomers waste real money guessing between them. What each certification is, how they differ, and how to choose.
Compensation · 2026-07-23
The 'average CRA salary' is at least four different numbers
Ask four salary sites what a CRA earns and you get $78,900, $95,000, $100,500, and $113,900. None is wrong. All are useless for the thing you actually need.
Industry · 2026-07-23
The biotech funding cycle is the tide under your job
Venture money and IPOs decide how many trials start, which decides CRO bookings, which decides hiring. Following the funding is following your own job security upstream.
Compensation · 2026-07-23
The contract CRA market the salary sites can't see
Aggregators show contract CRAs earning about the same hourly as salaried ones. The real independent-contractor market runs at nearly double that, and the gap is the whole point.
Industry · 2026-07-23
What a CRO merger does to your job
The industry consolidated into a handful of giants through a decade of megadeals. The history is public, and so is the pattern of what happens to staff when the deals close.
Employer files · 2026-07-23
The big CROs, ranked by their own employees
We pulled every major CRO's employee rating on the same day. The rankings are worth seeing, but the identical complaint running through all of them matters more.
Industry · 2026-07-23
Decentralized trials: what the hype gets wrong, and what it means for CRAs
Every conference says trials are going remote. The registry data says decentralization is real but early, concentrated in the wrong places, and reshaping the CRA role rather than ending it.
Compensation · 2026-07-23
Does a clinical research certification actually raise your pay?
Every salary figure that says certification pays comes from someone selling the certification. We went looking for independent evidence. There is almost none.
Employer files · 2026-07-23
Employer file: Medpace, where the financials and the reviews disagree
A founder-led, vertically integrated CRO growing fast on paper, and carrying the lowest employee ratings of any major CRO. The facts, the sentiment, and the gap between them.
Employer files · 2026-07-23
Employer file: Parexel, private equity's clinical research bet
One of the largest CROs, owned by private equity, and the highest-rated of the mega-CROs by its own staff, though the rating is slipping. The facts and the sentiment, kept separate.
Employer files · 2026-07-23
Employer file: Syneos Health, a merger inside a buyout
Built from a merger, taken private by a private-equity consortium in 2023, and marked by staff for layoffs ever since. The facts of the ownership, and what its people report.
Careers · 2026-07-23
FSP or full-service: the outsourcing model that decides your career shape
The industry is shifting toward functional service provider staffing, where you work badged inside a sponsor. It offers stability and a narrower job. Know the trade before you take it.
Industry · 2026-07-23
The recruitment crisis is the industry's oldest unsolved problem
Most trials miss their enrollment targets, many sites enroll no one, and the delays cost millions a day. The numbers behind the crisis, and why they are a job story.
Compensation · 2026-07-23
Pay transparency laws were supposed to fix this. Read the fine print.
Eighteen states now make employers post salary ranges. The research on what that actually did is sobering: pay barely moved, and the ranges got wide enough to be useless.
Careers · 2026-07-23
Should a clinical project manager get a PMP?
The PMP is a general project management credential, not a clinical one. For clinical trial managers weighing it, here is what it signals, what it costs, and the catch in its pay claims.
Careers · 2026-07-23
The RAC: the one credential regulatory affairs actually respects
Regulatory affairs has its own certification, and unlike most, it is aimed squarely at experienced professionals. What the RAC requires, what it costs, and who it is for.
Field guide · 2026-07-23
Risk-based monitoring and E6(R3): is the CRA travel role really shrinking?
The updated good clinical practice standard makes centralized monitoring a core pillar. What that means for source verification, site visits, and the future of the road-warrior CRA.
Compensation · 2026-07-23
What the salary sites say versus what employers actually filed
We pulled the same roles from Glassdoor, Indeed, ZipRecruiter, and Payscale. They disagree with each other by tens of thousands of dollars, and sometimes emit numbers that are simply broken.
Field guide · 2026-07-23
What CRO job ads actually demand now
We read what the current postings require for CRA, data management, and biostatistics roles. The specific systems and skills that show up again and again are the ones worth building.
Compensation · 2026-07-23
Where clinical research work actually concentrates
The jobs cluster in a handful of US metros led by one dominant hub, and the government's own wage data is too coarse to price them. Where the work is, and why the numbers stay fuzzy.
Industry · 2026-07-22
AI in Clinical Research: What's Real in 2026
What AI in clinical research actually does in 2026: real workflows, failure rates, FDA and EMA rules, and job impact, written for people who work in trials.
Industry · 2026-07-22
Anthropic is entering science. Clinical research is on the map.
The AI company behind Claude now sells a research workbench, runs its own drug program, and lists Medidata and ClinicalTrials.gov among its connectors. What that means for the people who run trials.
Field guide · 2026-07-22
The FDA inspection that can end a trial site
The FDA's bioresearch monitoring program inspects clinical trials, and the outcome is graded in three letters. What NAI, VAI, and OAI mean, and why the count is rising.
Field guide · 2026-07-22
Book-to-bill: the one number that predicts CRO hiring
Public CROs report a metric every quarter that forecasts their revenue years out, and their hiring with it. Here is how to read it before your employer's next reorg.
Industry · 2026-07-22
Bookings are up. Hiring is not. Why the two came apart.
Most of the big CROs are booking more work, yet cost-cutting and restructuring are running at the same time. The gap between a recovering book and a frozen headcount, explained.
Careers · 2026-07-22
Breaking into clinical research without monitoring experience
The catch-22 everyone hits: CRA jobs want CRA experience. The real entry paths that work, and what each one pays while you build the years.
Industry · 2026-07-22
China is now the world's number two trial location. That is a worker story.
By recruiting-trial count, China sits second only to the United States and far ahead of everyone else in Europe. Where trial sites go, monitoring work and wage pressure follow.
Compensation · 2026-07-22
Contractor economics: what a CRA contract rate really has to clear
An hourly rate that looks huge next to your salary can be a pay cut once you price in benefits, downtime, and self-employment tax. The math contractors actually need.
Careers · 2026-07-22
The CRA ladder: what actually moves you from I to II to senior
Titles in monitoring are inconsistent across companies, and promotions track things nobody writes down. The real progression, and what triggers each step.
Compensation · 2026-07-22
Why CRAs are almost invisible in the visa data
In a million federal wage filings, biostatisticians appear by the hundreds and CRAs barely at all. That gap is not a data quirk. It tells you something real about the job.
Compensation · 2026-07-22
What the quantitative roles actually clear: the H-1B filings
We processed a million federal visa filings to pull the real numbers for biostatistics, statistical programming, and data management. These are wages employers filed with the government.
Industry · 2026-07-22
The CRO scoreboard: reading the big five's Q1 2026 books
Five public CROs, five book-to-bill ratios, one uneven picture. What the latest quarter's bookings say about where clinical research demand is actually heading.
Industry · 2026-07-22
The map of drug-development layoffs: Research Triangle, Boston, and the coasts
The public layoff filings have addresses. Plot them and the cuts cluster in a few places. Where the drug-development pain is landing, and what the map does and does not show.
Field guide · 2026-07-22
If WARN cannot see your layoff coming, what can?
The public filings miss most clinical research cuts. Here are the earlier, quieter signals that actually predict a reduction, and how to read your own situation before the email arrives.
Employer files · 2026-07-22
Employer file: ICON
The world's second-largest CRO, built by a $12 billion acquisition, now navigating slow pharma spending. The public numbers, and the questions worth asking before you sign.
Field guide · 2026-07-22
FDA's AI guidance, explained for people who run trials
The January 2025 draft credibility framework in plain terms: the two-factor risk test, the seven steps, what is in scope, and what you actually have to produce.
Employer files · 2026-07-22
Fortrea's turnaround, measured in three quarters of bookings
Spun off from Labcorp and still posting GAAP losses, Fortrea is booking above 1.1 for the third straight quarter. The bull case, and the caveat, for the people who work there.
Employer files · 2026-07-22
Which clinical research employers lean hardest on the H-1B
The visa filings name the employer on every record. Sorting the clinical research roles by sponsor shows which CROs and sponsors reach overseas to staff the quantitative bench.
Field guide · 2026-07-22
How big is a trial, really? The enrollment numbers behind your workload
Most trials are far smaller than the headline mega-studies. The registry shows the median completed industry trial enrolled about 70 patients. What size means for the work.
Compensation · 2026-07-22
How much does a CRA actually make?
The average salary sites quote is too coarse to negotiate with. Here is the honest answer, by level and by source, using government filings instead of blended averages.
Employer files · 2026-07-22
ICON booked 1.42. Read the asterisk before you celebrate.
The strongest book-to-bill in the CRO group came with flat revenue and an accounting change. A worked example in reading a headline number the careful way.
Industry · 2026-07-22
The sponsor's number one sin is inadequate monitoring. That is a CRA story.
A quarter of FDA-inspected sponsors draw a citation, and the top finding is failing to monitor trials properly. Read as a labor signal, that is an argument about CRA headcount.
Industry · 2026-07-22
The clinical trial slowdown, in one number
Analysts keep saying pharma R&D spending is slow. The trial registry lets you see it directly. Industry trial starts peaked in 2021 and have run below that ever since.
Careers · 2026-07-22
Industry versus academic: which trials actually pay
Most trials in the registry are academic, not industry. But the paid clinical research careers cluster in the industry slice. Knowing the split tells you where to aim.
Employer files · 2026-07-22
IQVIA's $34 billion backlog, and what it means for the people who work it
The largest CRO on earth is carrying a record backlog and a steady book. A look at what that scale actually signals for hiring, and what it hides.
Field guide · 2026-07-22
How to look up what any employer actually filed to pay
The government publishes the real wages employers committed to for visa-sponsored roles. Here is how to find what a specific company filed for your title before you negotiate.
Field guide · 2026-07-22
Look up your own program before it looks you up
The same public registry that tracks the whole industry tracks your specific trial. Here is how to read it as an early-warning system for your own job.
Industry · 2026-07-22
Medpace grew revenue 26% and the stock fell. Here is why.
The fastest-growing CRO in the group posted a book-to-bill below 1.0, and the market punished it. A lesson in why bookings matter more than the quarter you are in.
Careers · 2026-07-22
Who is running the most trials right now
The registry names the sponsor on every trial. Rank the big pharma names by active recruitment and you get a directional map of where the sponsor-side demand is.
Compensation · 2026-07-22
Oncology runs clinical research, and the registry proves it
Cancer trials outnumber the next-largest therapeutic area roughly two to one. Where the trials concentrate is where the specialization, the mobility, and the pay concentrate too.
Industry · 2026-07-22
OpenAI wants science next. The CRO stocks noticed first.
OpenAI called 2026 its year of science, shipped a life sciences model, and signed Novo Nordisk and Eli Lilly. When the news broke, IQVIA and Charles River shares fell. That reaction is the story for the people who work there.
Compensation · 2026-07-22
Pharmacovigilance quietly pays the most
Among clinical research functions in the federal wage data, drug safety posts the highest median of all. Why the least glamorous corner of the industry pays the best.
Industry · 2026-07-22
Phase 2 is the graveyard: what trial phases mean for your job security
Not all phases fail at the same rate. The registry shows Phase 2 kills trials more often than any other, and it is also the most common phase. What that means for where you sit.
Field guide · 2026-07-22
Protocol, consent, records: the three failures behind most clinical citations
Strip the FDA's clinical warning letters down and almost all of them come back to three basics. What they are, real examples of each, and how sites actually lose them.
Industry · 2026-07-22
The registry names the sponsor, never the CRO
Half a million public trial records, and the CROs that do the work are almost invisible in them. The same transparency gap that hides layoffs hides who actually runs your industry.
Compensation · 2026-07-22
Regulatory affairs has the widest pay range in clinical research
The federal filings put regulatory affairs at a middling median but an enormous spread, from the low $80,000s to nearly $200,000. What that range says about the career.
Compensation · 2026-07-22
What sponsor side actually pays, function by function
Everyone says sponsors pay more than CROs. The public record is messier than that. What the filings show for the same job on the pharma side of the table.
Careers · 2026-07-22
Why sponsors quietly screen sites on inspection history
An FDA finding does not just cost remediation. It can make a site un-selectable and an investigator un-hirable. How inspection history follows a career, and how to check it.
Compensation · 2026-07-22
Statistical programming and biostatistics: the best-paid seats in the trial
The quantitative functions clear six figures on the public record and climb from there. What the filings show, and why the SAS-to-R shift matters for your next raise.
Compensation · 2026-07-22
The wage-level game: how employers file clinical research salaries
Every visa filing carries a government wage level from I to IV. The mix across clinical research reveals how employers classify the jobs, and where they file near the floor.
Compensation · 2026-07-22
Beyond base: the parts of your pay the offer letter buries
Two offers with the same base can be thousands apart once bonus, per diem, equity, and travel policy are priced in. How to compare total compensation honestly.
Field guide · 2026-07-22
Remote, hybrid, or on the road: what clinical research roles actually require
Job ads say remote. Travel percentages say otherwise. A function-by-function look at which clinical research roles are genuinely home-based and which just say so.
Industry · 2026-07-22
The layoff filings say clinical research is fine. They are wrong.
The big clinical CROs barely appear in the public WARN record, even in a soft market. That absence is not good news. It is a measurement problem, and here is what it hides.
Employer files · 2026-07-22
Layoff file: Charles River, and what the preclinical side is cutting
One of the few drug-development names with a thick public layoff record. Sixteen filings since 2014 show where the preclinical and manufacturing cuts are landing, and why the pattern matters.
Employer files · 2026-07-22
Layoff file: Thermo Fisher, and why you cannot find PPD in the numbers
Thermo Fisher owns one of the largest clinical CROs. Its public layoff record runs to 47 filings, and almost none of them are the CRO. A lesson in reading a conglomerate.
Industry · 2026-07-22
WARN watch: reading the layoff record so you do not have to
A recurring sweep of the public layoff filings that touch clinical research. This edition: what the record shows in mid-2026, and what it conspicuously does not.
Field guide · 2026-07-22
A warning letter is a CAPA avalanche. Guess who does the digging.
The FDA letter is one page. The work it triggers is months. A field guide to what actually happens after a 483 or a warning letter, and who absorbs it.
Industry · 2026-07-22
What the FDA actually cites when it inspects a trial
The violations behind clinical warning letters are strikingly consistent year after year. The recurring citations, with real recent examples, and what they say about the work.
Industry · 2026-07-22
Why trials actually die: what 34,000 terminations reveal
The public registry records every trial that gets killed, and why. We read the reasons across thousands of terminated industry trials. Enrollment is the number one killer, and that is a worker story.
Careers · 2026-07-22
Will AI replace CRAs? What the evidence actually says
The scariest headlines come from companies selling courses, and the boldest automation numbers from companies selling agents. The verified evidence says something quieter.
Industry · 2026-07-18
What AI actually does in statistical programming right now
Vendor decks promise automated submissions. The papers programmers write themselves describe something narrower, and they are missing one thing: numbers.
Compensation · 2026-07-18
Where the salary numbers come from
The salaries page holds three kinds of evidence side by side and refuses to blend them. How to read the figures, and what the public record already shows.
About Open Label · 2026-07-17
The anonymity rules we run on
Exactly how survey datapoints, quotes, and future community accounts are protected, written down before we asked anyone for anything.
Compensation · 2026-07-16
How to benchmark a CRA offer when Glassdoor fails you
Generic salary sites flatten the dimensions that actually move clinical research pay. Here is the checklist that matters.
Careers · 2026-07-15
CRO versus sponsor side: the real math of the move
The most common career question in clinical research, priced out beyond the base salary.
Compensation · 2026-07-14
Per diems: the road money nobody itemizes
For traveling CRAs, per diem structure can quietly move total compensation by thousands a year. Know the variants before you sign.
Compensation · 2026-07-13
Contract or FTE: how to price the difference
Contract rates look bigger. Sometimes they are. A working method for comparing a 1099 rate against a salaried offer.
Industry · 2026-07-12
Why every CRO is always hiring
CRA turnover has run between roughly 22 and 30 percent in recent years. What that number does to studies, sites, and your leverage.
Industry · 2026-07-11
How layoffs become public before the all-hands
US employers above a certain size must file advance notice of mass layoffs. Those WARN filings are public, and almost nobody in this industry reads them.
Field guide · 2026-07-10
What a monitoring visit actually is
For the people adjacent to clinical research, and the people about to join it: the real anatomy of the CRA's defining ritual.
Employer files · 2026-07-09
Employer file: IQVIA
The largest CRO on earth, by the public numbers, and the questions worth asking before you sign there.
Careers · 2026-07-08
Interview questions that reveal the real workload
The offer letter tells you the salary. These questions tell you what the job actually costs.